Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 378

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Iuliana Vaxman, Shaji Kumar, Inbar Cohen, Shai O. Shimony, Angela Dispenzieri, Francis Buadi, David Dingli, Martha Lacy, Eli Muchtar, Prashant Kapoor, William J. Hogan, Suzanne R Hayman, Nelson Leung, Wilson I. Gonsalves, Taxiarchis Kourelis, Rahma M Warsame, Morie A. Gertz

Blood (2024) 144 (Supplement 1): 7078.

https://doi.org/10.1182/blood-2024-205062

Published: 2024

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

Huihuang Yan, Suganti Shivaram, Hongwei Tang, Hans Anderson, Shulan Tian, Michael D Howe, Abiola Bolarinwa, Cinthya Zepeda Mendoza, Stacey Lehman, Leif Bergsagel, Esteban Braggio, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2024-208503

Published: 2024

Journal Articles

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4704.

https://doi.org/10.1182/blood-2024-201052

Published: 2024

Journal Articles

Immunomodulatory Effects of MEK Inhibition in Multiple Myeloma

Chaitanya Acharya, Reyka G. Jayasinghe, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn Jay Cho, Shaji Kumar, George Mulligan

Blood (2024) 144 (Supplement 1): 6863.

https://doi.org/10.1182/blood-2024-210989

Published: 2024

Journal Articles

Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis

Anand Pabmanabhan, Noah Splinter, Emily Mauch, Adam Kanack, Rajiv K Pruthi, Dong Chen, Angela Dispenzieri, Shaji Kumar, Damon E. Houghton

Blood (2024) 144 (Supplement 1): 3996.

https://doi.org/10.1182/blood-2024-207999

Published: 2024

Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau

Blood (2024) 144 (Supplement 1): 4757.1.

https://doi.org/10.1182/blood-2024-199752

Published: 2024

Journal Articles

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Blood (2024) 144 (Supplement 1): 4685.1.

https://doi.org/10.1182/blood-2024-208457

Published: 2024

Journal Articles

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2024-208468

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 83.

https://doi.org/10.1182/blood-2024-202098

Published: 2024

Journal Articles

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Rahul Banerjee, Amber R. Fritz, Othman S. Akhtar, Ciara Louise Freeman, Andrew J. Cowan, Nina Shah, Heather J. Landau, Shaji Kumar, Dan T. Vogl, Yvonne A. Efebera, Philip L. McCarthy, David H. Vesole, Adam Mendizabal, Amrita Y Krishnan, George Somlo, Edward A. Stadtmauer, Marcelo C. Pasquini

Blood (2024) 144 (Supplement 1): 81.

https://doi.org/10.1182/blood-2024-199615

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Blood (2024) 144 (Supplement 1): 7039.

https://doi.org/10.1182/blood-2024-210376

Published: 2024

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Journal Articles

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4716.

https://doi.org/10.1182/blood-2024-211755

Published: 2024

Journal Articles

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Jacob T Shreve, Michael D Howe, Emmanuel Contreras Guzman, Charalampos Charalampous, Wilson I. Gonsalves, Francis Buadi, Taxiarchis Kourelis, Suzanne R Hayman, Morie A. Gertz, Rafael Fonseca, S. Vincent Rajkumar, Surendra Dasari, Matthew P. Thorpe, Stephen Broski, Shaji Kumar, Moritz Binder

Blood (2024) 144 (Supplement 1): 4711.

https://doi.org/10.1182/blood-2024-202022

Published: 2024

Journal Articles

Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease

Blood (2024) 144 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2024-208790

Published: 2024

Journal Articles

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Fan Wang, Heiko Babel, Vanessa Schmitt, Muhammad Erfan Uddin, Muhamed Baljevic, Peter M. Voorhees, Cesar Rodriguez, Shaji Kumar, Hira Mian, Anders Erik Svensson, Chetasi Talati, Sven Mensing, Rajeev M Menon, Benjamin Engelhardt, Akshanth R Polepally

Blood (2024) 144 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2024-206054

Published: 2024

Journal Articles

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7165.

https://doi.org/10.1182/blood-2024-211111

Published: 2024

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Autologous Stem Cell Transplantation for Multiple Myeloma Patients Whose Myeloma Defining Event Was Slim

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Immunomodulatory Effects of MEK Inhibition in Multiple Myeloma

Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Light Chain Multiple Myeloma - Clinical Characteristics and Outcomes

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma

Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease

Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Cytokine Profile Comparisons Among Cytokine Release Syndrome (CRS), Macrophage Activation-like Syndrome (MAS-L) and Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS) in CAR-T Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only